Brentuximab vedotin (Adcetris®) in therapy of system anaplastic large cell lymphoma. Case report

A A Semenova,M S Nikitina,M I Akhmedov,P A Zeynalova

doi:10.17650/1818-8346-2019-13-4-54-59

Abstract

The introduction of new monoclonal antibodies has become an integral part of the treatment of malignant tumors.Brentuximab vedotin (Adcetris®) – anti-D30 monoclonal antibody conjugated with monomethyluristatin E – has become a new drug registered since February 2016 in the Russian Federation (SGN-35; Adcetris®). The Food and Drug Administration approved the Adcetris® since August 2011 as a therapy for refractory/recurrent Hodgkin’s lymphoma and anaplastic large cell lymphoma.This article describes the clinical case of successful use of Brentuximab vedotin, accompanied by the development of a rare complication – tumor lysis syndrome – in an elderly patient with primary refractory ALK-negative anaplastic large cell lymphoma with massive eosinophilia.

Highlights

The introduction of new monoclonal antibodies has become an integral part of the treatment of malignant tumors
Brentuximab vedotin (Adcetris®) – anti-D30 monoclonal antibody conjugated with monomethyluristatin E – has become a new drug registered since February 2016 in the Russian Federation (SGN-35; Adcetris®)
This article describes the clinical case of successful use of Brentuximab vedotin, accompanied by the development of a rare complication – tumor lysis syndrome – in an elderly patient with primary refractory ALK-negative anaplastic large cell lymphoma with massive eosinophilia

Summary

Introduction

The introduction of new monoclonal antibodies has become an integral part of the treatment of malignant tumors. This article describes the clinical case of successful use of Brentuximab vedotin, accompanied by the development of a rare complication – tumor lysis syndrome – in an elderly patient with primary refractory ALK-negative anaplastic large cell lymphoma with massive eosinophilia. I. Brentuximab vedotin (Adcetris®) in therapy of system anaplastic large cell lymphoma.

Results

Conclusion